Comparative Pharmacology
Head-to-head clinical analysis: ILEVRO versus PROLENSA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ILEVRO versus PROLENSA.
ILEVRO vs PROLENSA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Nepafenac is a prodrug that is metabolized to amfenac, a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX) activity, reducing prostaglandin synthesis.
Bromfenac is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2) enzymes, reducing prostaglandin synthesis and thereby decreasing inflammation, pain, and angiogenesis in the eye.
1 drop of the 0.3% ophthalmic solution administered to the affected eye(s) four times daily.
Adults: 1 drop in affected eye(s) twice daily (morning and evening) for 2 weeks.
None Documented
None Documented
Terminal elimination half-life of amfenac is approximately 0.7 hours in plasma, but due to prolonged residence in ocular tissues, the clinical effect lasts up to 24 hours with once-daily dosing.
Terminal elimination half-life is approximately 1.5 hours for the ocular route; after systemic absorption, half-life is about 4.5 hours. The short half-life limits systemic exposure but requires multiple daily dosing for sustained ocular effect.
Nepafenac is extensively metabolized, and its active metabolite amfenac is primarily excreted renally (approximately 80% as metabolites, including amfenac glucuronide, and 20% as unchanged drug in urine). Biliary/fecal excretion accounts for less than 10%.
Primarily renal elimination (approximately 70% of the dose as unchanged drug and metabolites), with the remainder excreted in feces via biliary secretion (approximately 30%).
Category C
Category C
Ophthalmic NSAID
Ophthalmic NSAID